Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcom...
Main Authors: | Ewelina Jakielska, Paweł Głuszak, Marta Walczak, Wiesław Bryl |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2023-03-01
|
Series: | Gastroenterology Review |
Subjects: | |
Online Access: | https://www.termedia.pl/Effects-of-PCSK9-inhibitors-on-metabolic-associated-fatty-liver-disease-a-short-review,41,50394,1,1.html |
Similar Items
-
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
by: Malak Alannan, et al.
Published: (2022-12-01) -
Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020-01-01) -
PCSK9 and the Gut-Liver-Brain Axis: A Novel Therapeutic Target for Immune Regulation in Alcohol Use Disorder
by: Ji Soo Lee, et al.
Published: (2021-04-01) -
Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
by: Thomas Grewal, et al.
Published: (2022-01-01) -
High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes
by: Krisztina Németh, et al.
Published: (2023-03-01)